Clinical Trial Update: Efficacy of Ferric Carboxymaltose With or Without EPO Reducing Red-cell Transfusion Packs in Hip Fracture Perioperative Period [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ferric carboxymaltose with or without erythropoietin to reduce red blood cell transfusion needs in the perioperative period for hip fra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hip Fracture

Drugs mentioned

• Erythropoietin (erythropoietin)
• Ferric carboxymaltose (ferric carboxymaltose)

Snippet

Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Conditions: Hip Fractures | Phase 3 | Status: COMPLETED